Drug intelligence / Profile preview

MED402

Development stage: Preclinical
Lead developer: Medley Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

MED402 is a novel tumor-targeted radioligand therapy (RLT) being developed by Medley Therapeutics for the treatment of solid tumors. The drug is designed to deliver a radionuclide payload directly to cancer cells by utilizing a targeting molecule that binds to specific tumor-associated antigens. This mechanism allows for localized delivery of ionizing radiation to the tumor microenvironment, aiming to induce DNA damage and cell death in malignant cells while minimizing exposure to healthy tissues. MED402 is currently in the preclinical and IND-enabling stages of development.

Beyond the preview

Go deeper on MED402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MED402.

Explore the full profile